Data completeness
3/8 — Basic
CODEINE SULFATE by Hikma is mu-opioid receptor, but with a much weaker affinity than morphine. Approved for mild to moderate pain, where treatment with an opioid is appropriate, for which alternative treatments are inadequate. First approved in 2011.
Drug data last refreshed 17h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Codeine sulfate is an oral solution containing a weak mu-opioid receptor agonist used for mild to moderate pain when alternative treatments are inadequate. The drug's analgesic properties are thought to derive from conversion to morphine, though the exact mechanism remains incompletely understood. It represents a traditional, well-established pain management option with limited clinical innovation.
Peak
Product is at peak lifecycle with moderate competitive pressure (30/100), indicating stable but not expanding commercial opportunities for brand teams.
Mechanism of Action
mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine, although the exact mechanism of analgesic action remains unknown.
Worked on CODEINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.